BioMarin Pharmaceutical Inc. (BMRN) financial statements and ratios from SEC XBRL: revenue $3.4B (TTM), net margin 10.8%, revenue growth 19.9% YoY, P/E 176.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $3.22B |
| Revenue (TTM) | $3.4B |
| Net Margin | 10.8% |
| Operating Margin (TTM) | 4.4% |
| Net Debt / EBITDA | 14.9 |
| Revenue Growth (YoY) | 19.9% |
| EPS Growth (YoY) | -81.6% |
| FCF Growth (YoY) | -17.2% |
| P/E Ratio | 176.9 |
| EV / EBITDA | 73.0 |
| Price / Book | 2.04 |
| Price / Sales | 3.79 |
| FCF Yield | 5.7% |
| Altman Z-Score | 6.24 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
BMRN overview · BMRN earnings · BMRN KPIs · BMRN documents · BMRN ownership · BMRN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.